HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.

Authors: Jong Chul Park, Lisa F. Licitra, Aditya V. Shreenivas, Yungpo Su, Santosh M. Nair, Andrea S. Teague, Douglas Adkins, Siddharth Sheth, Hye Ryun Kim, Jorge Martinalbo, Yaiza Diaz De Durana, Lane Senne, James Kalabus, Josep Garcia, Dan Paul Zandberg

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps6109

Source: Full article

---

Abstract

TPS6109